Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

Similar articles for PubMed (Select 23326931)

1.

[Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].

Agbalaka A, Schwenke K, Litzenburger B.

MMW Fortschr Med. 2012 Dec 17;154 Suppl 4:123-30. German.

PMID:
23326931
2.

[Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].

Schwittay A, Schumann C, Litzenburger BC, Schwenke K.

MMW Fortschr Med. 2012 Oct 4;154 Suppl 3:85-93. German.

PMID:
23133884
3.
4.

Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.

Schwittay A, Schumann C, Litzenburger BC, Schwenke K.

J Pain Palliat Care Pharmacother. 2013 Aug;27(3):225-34. doi: 10.3109/15360288.2013.816406. Epub 2013 Aug 19.

PMID:
23957433
5.

Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.

Steigerwald I, Schenk M, Lahne U, Gebuhr P, Falke D, Hoggart B.

Clin Drug Investig. 2013 Sep;33(9):607-19. doi: 10.1007/s40261-013-0102-0.

6.

Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists.

Strick V.

Curr Med Res Opin. 2014 Oct;30(10):2085-92. doi: 10.1185/03007995.2014.939166. Epub 2014 Jul 15.

PMID:
24983745
7.

[Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d.]

Richter U, Waldmann-Rex S, Lehmann U.

Wien Klin Wochenschr. 2014 Nov 20. [Epub ahead of print] German.

PMID:
25409951
8.

Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.

Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I.

Adv Ther. 2013 Mar;30(3):229-59. doi: 10.1007/s12325-013-0015-6. Epub 2013 Mar 7.

PMID:
23475406
9.

Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.

Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M.

Pain Physician. 2014 Jul-Aug;17(4):329-43.

10.

Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.

Steigerwald I, Müller M, Davies A, Samper D, Sabatowski R, Baron R, Rozenberg S, Szczepanska-Szerej A, Gatti A, Kress HG.

Curr Med Res Opin. 2012 Jun;28(6):911-36. doi: 10.1185/03007995.2012.679254. Epub 2012 May 9.

PMID:
22443293
11.

Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients.

Schikowski A, Krings D, Schwenke K.

J Pain Res. 2014 Dec 22;8:1-8. doi: 10.2147/JPR.S72150. eCollection 2015.

12.

Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T.

Clin Drug Investig. 2014 Jul;34(7):501-11. doi: 10.1007/s40261-014-0204-3.

13.

Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.

Ikenberg R, Hertel N, Moore RA, Obradovic M, Baxter G, Conway P, Liedgens H.

J Med Econ. 2012;15(4):724-36. doi: 10.3111/13696998.2012.670174. Epub 2012 Mar 28. Erratum in: J Med Econ. 2012;15(6):1216.

PMID:
22364286
14.
15.

Efficacy of tapentadol ER for managing moderate to severe chronic pain.

Afilalo M, Morlion B.

Pain Physician. 2013 Jan;16(1):27-40. Review.

16.

Tapentadol extended release for chronic pain patients.

Taylor R, Pergolizzi JV, Raffa RB.

Adv Ther. 2013 Jan;30(1):14-27. doi: 10.1007/s12325-013-0002-y. Epub 2013 Jan 15. Review.

PMID:
23328938
17.

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.

Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C.

Curr Med Res Opin. 2011 Jan;27(1):151-62. doi: 10.1185/03007995.2010.537589.

PMID:
21162697
18.

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.

Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J.

Clin Drug Investig. 2010;30(8):489-505. doi: 10.2165/11533440-000000000-00000.

PMID:
20586515
19.

Tapentadol extended release: in adults with chronic pain.

Hoy SM.

Drugs. 2012 Feb 12;72(3):375-93. doi: 10.2165/11208600-000000000-00000. Review.

PMID:
22316353
20.

Systematic review of tapentadol in chronic severe pain.

Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, Kleijnen J, Stürzebecher S.

Curr Med Res Opin. 2011 Oct;27(10):1907-30. doi: 10.1185/03007995.2011.611494. Epub 2011 Sep 12. Review. Erratum in: Curr Med Res Opin. 2012 Jan;28(1):148.

PMID:
21905968
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk